Abstract
Regulator of a vast array of vital cellular processes including cell-cycle progression, apoptosis and antigen presentation, the proteasome represents a major therapeutic target. Therefore, selective inhibitors of the proteasome are promising candidates to develop new treatments for diseases like inflammation, immune diseases and cancer. For proof, the boronic acid, Bortezomib has been approved for treating incurable multiple myeloma in 2003 and mantle lymphoma in 2006 and five others proteasome inhibitors are currently in clinical trials for treatment of different cancers. These compounds and many described proteasome inhibitors interact covalently with the active site of the enzyme through an electrophilic reactive function. Non-covalent inhibitors, mainly peptides, pseudopeptides and some organic compounds, have been less widely investigated. Devoid of reactive function prone to nucleophilic attack, they could offer the advantage of an improved selectivity, a less excessive reactivity and instability which are often associated with side effects in therapeutics. This review highlights the current state of research in the field of non-covalent proteasome inhibitors.
Keywords: Proteasome, anti-cancer drugs, non-covalent inhibitors, natural peptides, pseudopeptides, small synthetic molecules.
Current Pharmaceutical Design
Title:Non-Covalent Proteasome Inhibitors
Volume: 19 Issue: 22
Author(s): Julia Kaffy, Guillaume Bernadat and Sandrine Ongeri
Affiliation:
Keywords: Proteasome, anti-cancer drugs, non-covalent inhibitors, natural peptides, pseudopeptides, small synthetic molecules.
Abstract: Regulator of a vast array of vital cellular processes including cell-cycle progression, apoptosis and antigen presentation, the proteasome represents a major therapeutic target. Therefore, selective inhibitors of the proteasome are promising candidates to develop new treatments for diseases like inflammation, immune diseases and cancer. For proof, the boronic acid, Bortezomib has been approved for treating incurable multiple myeloma in 2003 and mantle lymphoma in 2006 and five others proteasome inhibitors are currently in clinical trials for treatment of different cancers. These compounds and many described proteasome inhibitors interact covalently with the active site of the enzyme through an electrophilic reactive function. Non-covalent inhibitors, mainly peptides, pseudopeptides and some organic compounds, have been less widely investigated. Devoid of reactive function prone to nucleophilic attack, they could offer the advantage of an improved selectivity, a less excessive reactivity and instability which are often associated with side effects in therapeutics. This review highlights the current state of research in the field of non-covalent proteasome inhibitors.
Export Options
About this article
Cite this article as:
Kaffy Julia, Bernadat Guillaume and Ongeri Sandrine, Non-Covalent Proteasome Inhibitors, Current Pharmaceutical Design 2013; 19 (22) . https://dx.doi.org/10.2174/1381612811319220016
DOI https://dx.doi.org/10.2174/1381612811319220016 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Use of MicroRNAs in Cancer
Anti-Cancer Agents in Medicinal Chemistry Cancer Cell Permeability-Glycoprotein as a Target of MDR Reverters: Possible Role of Novel Dihydropyridine Derivatives
Current Drug Targets Chemically Functionalized Carbon Nanotubes: Emerging Vectors for Cell Therapy
Mini-Reviews in Medicinal Chemistry Bioactive Polyphenols from Grapes and Wine Emphasized with Resveratrol
Current Pharmaceutical Design On the Power of Additional and Complex Chromosomal Aberrations in CML
Current Genomics Targeted Enzyme Prodrug Therapies
Mini-Reviews in Medicinal Chemistry Use of the Non-Toxic Cryoprotectant Trehalose Enhances Recovery and Function of Fish Embryonic Stem Cells Following Cryogenic Storage
Current Stem Cell Research & Therapy Immunotherapy of Melanoma
Current Molecular Pharmacology Anti-GD2 Antibody Therapy for GD2-Expressing Tumors
Current Cancer Drug Targets Nucleic Acids as Therapeutic Agents
Current Topics in Medicinal Chemistry Recent Advances in Herbal Nanomedicines for Cancer Treatment
Current Molecular Pharmacology MicroRNAs in the Intracellular Space, Regulation of Organelle Specific Pathways in Health and Disease
MicroRNA Latest Advancements on Serotonin and Dopamine Transporters in Lymphocytes
Mini-Reviews in Medicinal Chemistry Current View on the Mechanism of Action of Perifosine in Cancer
Anti-Cancer Agents in Medicinal Chemistry Lipid Nanoparticles and their Application in Nanomedicine
Current Pharmaceutical Biotechnology Toxicity and Efficacy of Benzamide Riboside in Cancer Chemotherapy Models
Current Medicinal Chemistry Peptido-Targeting of the Mitochondrial Transition Pore Complex for Therapeutic Apoptosis Induction
Current Pharmaceutical Design Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology The Membrane-targeted Alkylphosphocholine Erufosine Interferes with Survival Signals from the Extracellular Matrix
Anti-Cancer Agents in Medicinal Chemistry Aminobisphosphonates and Toll-Like Receptor Ligands: Recruiting Vγ9Vδ2 T Cells for the Treatment of Hematologic Malignancy
Current Medicinal Chemistry